| Autor: |
Saleem, Shifa Khaja, Decker, Sarah, Kissel, Sandra, Bauer, Marcus, Chernyakov, Dmitry, Bräuer-Hartmann, Daniela, Aumann, Konrad, Wickenhauser, Claudia, Herling, Marco, Skorobohatko, Oleksandra, Mathew, Nimitha, Schmidt, Cornelius, Klein, Claudius, Follo, Marie, Dierks, Christine |
| Zdroj: |
The Journal of Experimental Medicine; January 2025, Vol. 222 Issue: 1 pe20230681-e20230681, 1p |
| Abstrakt: |
Inhibition of the proximal B cell receptor (BCR) signaling pathway by BTK inhibitors is highly effective in the treatment of CLL, but drug resistance or intolerance occurs. Here, we investigated c-Jun N-terminal protein kinase 1 (JNK1) as an alternative drug target in the distal BCR pathway. JNK1 was preferentially overexpressed and activated in poor prognostic CLL with unmutated IGHV. Proximal BCR inhibition (BTK, PI3K, or SYK inhibitors) or SYK knockdown efficiently dephosphorylated JNK1, identifying JNK1 as a critical BCR downstream kinase in CLL. JNK1 inhibition induced apoptosis in primary CLL cells, resulting in the downregulation of BCL2, MCL1, and c-JUN. JNK1 inhibition in patient-derived CLL xenografted mice and Eµ-TCL1-tg mice prevented CLL progression, reduced splenic infiltration, and restored T cell function and normal hematopoiesis. JNK1 inhibitors even remained effective in ibrutinib refractory CLL. In conclusion, our study revealed JNK1 as a promising drug target in CLL downstream of the BCR, overcoming ibrutinib resistance, blocking the protective microenvironment, and improving CLL-specific immunosuppressive mechanisms. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
